GOSSAMER BIO INC (GOSS)

US38341P1021 - Common Stock

0.7885  -0.02 (-2.65%)

Buy % Consensus

79

ChartMill assigns a Buy % Consensus number of 79% to GOSS. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 6.09. This target is 672.12% above the current price.
GOSS was analyzed by 16 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about GOSS.
In the previous month the buy percentage consensus was at a similar level.
GOSS was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 0.790.515.106.0915.75 - -35.95% 546.80% 672.12% 1,897.46%
Up and Down Grades
Date Firm Action Rating
2024-03-27 Piper Sandler Maintains Overweight -> Overweight
2024-03-06 Wedbush Reiterate Outperform -> Outperform
2024-03-06 Goldman Sachs Maintains Buy -> Buy
2024-03-06 HC Wainwright & Co. Reiterate Buy -> Buy
2024-01-08 HC Wainwright & Co. Maintains Buy -> Buy
2023-12-19 Wedbush Reiterate Outperform -> Outperform
2023-11-10 Wedbush Maintains Outperform -> Outperform
2023-08-11 Wedbush Reiterate Outperform -> Outperform
2023-08-10 HC Wainwright & Co. Reiterate Buy -> Buy
2023-07-26 Wedbush Maintains Outperform -> Outperform
2023-07-26 HC Wainwright & Co. Reiterate Buy -> Buy
2023-07-21 Wedbush Reiterate Outperform -> Outperform
2023-05-11 HC Wainwright & Co. Reiterate Buy -> Buy
2023-03-21 Barclays Maintains Equal-Weight
2023-03-07 Raymond James Downgrade Outperform -> Market Perform
2023-03-01 Guggenheim Initiate Neutral
2022-12-08 HC Wainwright & Co. Maintains Buy
2022-12-07 SMBC Nikko Downgrade Outperform -> Neutral
2022-12-07 UBS Maintains Buy
2022-12-07 SVB Leerink Maintains Outperform
2022-12-07 Barclays Downgrade Overweight -> Equal-Weight
2022-12-07 Raymond James Maintains Outperform
2022-12-07 JP Morgan Downgrade Neutral -> Underweight
2022-12-07 Goldman Sachs Maintains Buy
2022-11-17 Raymond James Maintains Outperform
2022-10-20 Goldman Sachs Initiate Buy
2022-09-21 JP Morgan Initiate Neutral
2022-09-19 Wedbush Initiate Outperform
2022-08-18 Barclays Maintains Overweight
2022-08-10 Raymond James Maintains Outperform